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New  treatments  are  urgently  required  to treat infections  caused  by multi-drug  resistant  Acinetobacter
baumanni,.  To address  this  need,  a new  formulation  of Minocin®, (minocycline  for injection)  has  been
developed  that  allows  for higher  doses  of minocycline  to  be administered.  Phase  1 clinical  trials  were
conducted  in  healthy  volunteers  to assess  the  safety  and  pharmacokinetics  (PK)  of this  new  formulation
at  higher  doses.  In  order  to generate  PK  data,  novel,  selective  and  simple  HPLC-MS/MS  based  assays  were
developed  and  validated  for the  determination  of  minocycline  (MC) in  human  plasma  and  urine.  The
respective  working  ranges  were  0.05 to  30  mg/L  and  0.1  to 30 mg/L.  Removal  of  endogenous  proteins
with  trichloroacetic  acid was  used  as a  simple  means  of  extracting  MC  from  the  samples.  An  analogue,
tetracycline  was  used  as the  internal  standard  (IS). Chromatographic  separation,  including  that  of  MC
from  its 4-epimer  (4-EMC),  was  achieved  on a Waters  XBridge  BEH  C18 column  (50  x 4.6  mm ID,  5  m)
with  gradient  elution.  The  mobile  phases  comprised  water  containing  5  mM  ammonium  formate  at  a  pH
of 2.5,  and  methanol  containing  5 mM  ammonium  formate.  The internal  standard  (IS)  was  tetracycline,
a  structural  analogue  of  minocycline.
The  methods  were  fully  validated  and  met  regulatory  acceptance  criteria  for  intra-run  and  inter-run
accuracy  and  precision,  carryover,  dilution  integrity  and  matrix  effects.  Mean  extraction  recoveries  ranged
between  64.3%  and  84.6%  for MC  and  64.3%  for the  IS. There  was  no signiﬁcant  ion suppression  or  enhance-
ment  for  MC  or  the  IS. The  validated  assays  were  successfully  applied  to  1423  plasma  and  689  urine
samples  from  a  Phase  1 clinical  study.
There was  no evidence  of instability,  or signiﬁcant  interconversion  between  MC  and 4-EMC,  in  stored
clinical  samples,  spiked  plasma  and  urine  samples,  or  their  extracts,  under  various  test  conditions.
© 2019  Published  by  Elsevier  B.V.. IntroductionTetracyclines (TCs) are important broad spectrum antibiotics
hich are active against gram-positive and gram-negative bacteria.
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731-7085/© 2019 Published by Elsevier B.V.They were ﬁrst used in clinical practice in the 1950′s. Minocycline
(MC, Fig. 1) is a second generation semi-synthetic tetracycline that
was ﬁrst described in the 1960s and became commercially avail-
able in 1971 [1–3] MC,  reportedly the most lipophilic tetracycline, is
absorbed rapidly, readily crosses the blood–brain barrier [4–6] and
has potential for treating a wide range of non-infectious illnesses
[7].
MC has been proposed as a treatment for infections caused by
increasingly multi-drug resistant (MDR) Acinetobacter baumanni
(AB) and methicillin-resistant Staphylococcus aureus (MRSA) [8,9].
The risk of MDR  AB to public health has been highlighted by the
US government [10,11] and the European Commission [12]. MC  is
active against strains that are resistant to newer TCs such as doxy-
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3.0, 5.0, 7.5, 15, 25 and 30 mg/L. Calibration standards were pre-
pared in urine at the following concentrations: 0.1 (LLOQ), 0.2 (2 xFig. 1. Structures of Minocycline, 4-Epiminocycline and Tetracycline.
ycline and tigecycline [13]. Intravenous (IV) formulations of MC
ave been reviewed for their effectiveness in treating MDR  AB [14].
o address this need, a new formulation of Minocin®, (minocycline
or injection) has been developed that allows for higher doses of
inocycline to be administered. [15]. Oral and IV formulations,
ith a maximum dose of 400 mg  (200 mg  twice daily), have been
pproved in the US for several decades but only oral doses have
een approved for use in the countries of the EU. A Phase 1 clini-
al study, was performed to investigate the safety, tolerability and
harmacokinetics (PK) of single and multiple doses of Minocin®,
n healthy adults [15]. This study included doses higher than those
pproved in the US. MC  was developed prior to the widespread use
f Pharmacokinetics-Pharmacodynamics (PK-PD) modelling when
linical doses were not systematically evaluated or optimised [16].
Bioanalytical methods, based on HPLC-MS/MS, for the determi-
ation of MC  in plasma and urine were developed to support this
tudy. Urine analysis was needed to conﬁrm the minor role of renal
learance at higher doses [17].
Numerous methods based on HPLC and HPLC-MS/MS have
een reported for measuring MC  in a wide variety of matrices, as
eviewed thoroughly by Patel et al [18]. However, to our knowl-
dge, only two publications have reported the use of HPLC-MS/MSFig. 2. Calculated Log D vs pH for MC and 4-EMC.
for the analysis of MC  in human plasma [18,19] and none for urine.
Araujo et al [19] describe a limited validation.
MC,  like other TCs [20–22], readily epimerises at the 4-position
to 4epiminocycline (4-EMC, Fig. 1) in vitro and in vivo [23]. Accord-
ing to Nelis et al [24] this could happen in the bladder. Epimers
of TCs are reported to have different antibacterial and toxicological
properties [22,25,26]. They pose a signiﬁcant challenge for selective
bioanalysis, being isobaric with the parent drug and having very
similar physicochemical properties (Fig. 2). Insufﬁcient chromato-
graphic resolution leads to overestimates of the levels of parent
drug, especially at later time points after dosing. Patel et al [18]
describe the only reported method that uses HPLC-MS/MS to anal-
yse MC  in human plasma whilst separating 4-EMC.
Trichloroacetic acid (TCA) was  used to extract MC  from human
plasma and urine samples in the assays described herein. A struc-
tural analogue, tetracycline (Fig. 1) was  used as the internal
standard (IS).
2. Materials and methods
2.1. Chemicals and reagents
The following chemicals were purchased from Sigma-Aldrich
(St. Louis, MO,  USA): minocycline hydrochloride, tetracycline,
ammonium formate and trichloroacetic acid (TCA). 4-EMC was
obtained from Santa Cruz Biotechnology (Dallas, Texas, USA).
Water, methanol and formic acid were obtained from Fisher Scien-
tiﬁc (Loughborough, UK). Dimethyl sulfoxide (DMSO) was  obtained
from VWR  International (Radnor, PA, USA). Non-sterile, citrated
dialysed human plasma with K2 ethylenediaminetetraacetic acid
(EDTA) was purchased from TCS biosciences (Botolph Claydon,
UK). Urine was  provided by volunteers in-house. All reagents were
HPLC-grade or its equivalent, at the minimum.
2.2. Preparation of solutions, calibration standards, and quality
controls
All re-usable glassware was washed with water containing 0.1%
v/v formic acid, water and methanol, then tested for contamination
prior to use. Stock solutions of MC  and IS were prepared in aque-
ous methanol, that of 4-EMC in DMSO. Intermediate and working
solutions were prepared by dilution with water. Calibration stan-
dards were prepared in plasma at the following concentrations:
0.05 (Lower limit of quantiﬁcation, LLOQ), 0.1 (2 x LLOQ), 0.5, 1.5,LLOQ), 0.5, 1.5, 3.0, 5.0, 7.5, 15, 25 and 30 mg/L. Low, medium and
high QCs were prepared at concentrations of 0.15, 7 and 24 and 0.3,
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Table 1
LC gradient.
Time
(min)
Mobile phase (%) Flow rate
(mL/min)
A B
0 90 10 0.8
0.5  90 10 0.8
5.5  60 40 0.8
5.6  0 100 0.8
5.7  0 100 1.5
6.1  0 100 1.5
6.2  90 10 1.5
7.2  90 10 1.5
7.4  90 10 0.8
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(obile phase A: water containing 5 mM ammonium formate (pH of 2.5).
obile phase B: water-methanol, 5/95 v/v containing 5 mM ammonium formate.
 and 24 mg/L in plasma and urine respectively. For the purposes
f the validations, additional QCs were prepared at the following
oncentrations: LLOQ and 2 x LLOQ. All solutions and test samples
ere stored at ca. -80 ◦C and allowed to reach room temperature on
he day of analysis. On each day of analysis, a ﬁnal IS working solu-
ion was prepared at a concentration of 1 mg/L in water containing
0% w/v TCA.
.3. Extraction of plasma and urine samples
100 L of sample was dispensed into a 0.5 mL  polypropylene
ppendorf® tube. The sample was then mixed thoroughly with
00 L of IS working solution. After being left to stand at ca. 4 ◦C for
0 min, the sample was centrifuged for 5 min  at 17,000 g. 100 L
f supernatant was then transferred to a glass HPLC vial contain-
ng 900 L of water. The ﬁnal extract was thoroughly mixed prior
o analysis. Full ranges of calibration standards were injected at
he start and end of each analytical run. Zero and blank samples,
ith and without IS respectively, were included with each set of
tandards.
.4. HPLC-MS/MS conditions
A Shimadzu Prominence® (Kyoto, Japan) LC system was cou-
led to a Sciex triple quadrupole 4000 QTRAP mass spectrometer
AB Sciex, Warrington, UK). Sciex Analyst v.1.5.1 software was  used
o control the HPLC-MS/MS system and collect the MS  data. High
urity nitrogen was supplied to the MS  by a Thyster-TF/1 genera-
or (F-DGSi, Every, France). The LC system consisted of a SIL20AC
utosampler, two LC-20AD pumps, a CTO-20 AC column oven and a
BM-20A controller. The autosampler was set a temperature of 4 ◦C
nd programmed to inject 5 L of each sample. Gradient separation
Table 1) was achieved, at a temperature of 40 ◦C, on a Waters (Mil-
ord, Massachusetts, USA) XBridge BEH C18 column (5 m,  130 Å,
0 x 4.6 mm ID, part no. 186003113) protected with an Upchurch
Hichrom, Reading, UK) precolumn ﬁlter unit ﬁtted with a 0.5 m
rit. Each LC injection cycle was 7.5 min  long. A 6-port, 2-way, Valco
alve (VICI AG, Schenkon, Switzerland) was set to divert eluate
ontaining the peaks of interest to the MS  from 3.5 to 5.5 min.
Mobile phase A comprised water containing 5 mM ammo-
ium formate, diluted from a 100 mM  stock solution buffered to
 pH of 2.5. Mobile phase B comprised water-methanol, 5/95 v/v,
nd 5 mM ammonium formate. The autosampler wash contained
ater-methanol, 50/50 v/v and was programmed to wash the injec-
ion needle before and after injection.
Multiple Reaction Monitoring (MRM)  data were collected by the
TM
S using a Turbo V source in electrospray ionisation (ESI) pos-
tive mode. The source temperature was set at 600 ◦C, ion spray
oltage at 5500 V, ion source gases 1 and 2 at 30 and 45, curtain gas
CUR) at 40 and collision gas (CAD) at 7. The MRM  transitions fornd Biomedical Analysis 169 (2019) 90–98
MC/4EMC and IS were set to m/z 458.4→441.2 and 445.3→410.3
respectively, with a dwell time of 150 ms.  MS parameters were
optimised by infusion of the analyte and IS into the HPLC-MS/MS
system.
2.5. Data analysis
Raw data were processed by Analyst v.1.5.1 using the ratio of
the peak areas of MC  to IS.
2.6. System suitability test solutions
The general performance and chromatographic resolution of the
HPLC-MS/MS system were evaluated at the start of each run by
injections of separate solutions of MC and IS, MC  and 4-EMC, in
water containing 0.5% w/v  TCA.
2.7. Validation of the assays
The assays in plasma and urine were validated following the
guidelines issued by the US Food and Drug Administration and
European Medicines Agency [27,28]. The following properties were
assessed: calibration model, accuracy and precision, selectivity,
carryover, matrix effects, dilution integrity, stability, ionisation
effects and extraction recoveries.
2.7.1. Calibration model
Calibration lines were constructed from non-zero standards
using a linear regression model with 1/x2 weighting [29].
2.7.2. Acceptance of runs
The calibration was  deemed acceptable when ≥66.7% of the non-
zero standards were within ≤15% of the nominal concentration;
within ≤ 20% at the LLOQ. Results from runs containing clinical sam-
ples were accepted when ≥66.7% of QC and at least one replicate
at each QC level were within ≤15% of the nominal concentra-
tion. Results from diluted samples were accepted when ≥66.7% of
dilution QCs were within ≤15% of the nominal concentration. In
the clinical study, concentrations below the LLOQ were deﬁned as
below the LLOQ (BLQ). Those above the ULOQ were reanalysed after
dilution.
2.7.3. Selectivity
Six individual samples of blank matrix were analysed. For
plasma, one lipaemic and one haemolysed sample were included.
Acceptable limits for selectivity were deﬁned as by the response
being ≤ 20% of the LLOQ for MC and ≤ 5% for the IS, as based on the
average response for the run.
2.7.4. Carryover
After the highest calibration (ULOQ) standard, three blank
samples were injected. Acceptable carryover was deﬁned as the
detector response for MC being ≤ 20% of the LLOQ and that for the
IS being ≤ 5% of the average for the IS throughout the run.
2.7.5. Accuracy, precision and LLOQ
Intra-run accuracy and precision was  determined from the mean
values from six replicates of each QC. Inter-run batch accuracy and
precision were determined using the mean values from duplicate
analyses at each QC concentration over eleven and nine runs for
plasma and urine respectively. Precision was  regarded as accept-
able if the coefﬁcient of variation (CV) was ≤ 15% for each QC  and
≤20% at the LLOQ. Accuracy was  regarded as acceptable if within
±15% of the nominal concentration for each QC and within ±20%
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Table  2
Ionisation effects and extraction recoveries.
Deproteinising agent1 QC Plasma2 Urine2
Extraction recovery (%) Ionisation effect (%) Extraction recovery (%) Ionisation effect (%)
Trichloroacetic acid (TCA)3
Low 64.3 109 115 111
Medium 84.6 112 119 98.3
High  77.8 110 112 102
IS  64.3 109 109 94.4
Acetonitrile (MeCN)
Low 64.0 61.4 66.2 79.9
Medium 83.8 58.7 52.0 70.0
High  66.9 68.4 55.1 64.1
IS  53.0 115 35.9 141
Methanol (MeOH)
Low 73.1 61.7 48.8 51.9
Medium 83.5 65.7 54.5 48.6
High  84.8 54.7 59.7 61.7
IS  55.8 99.0 44.9 95.7
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f1 Volumes of 1:1, 2:1, 4:1 for TCA, MeCN and MeOH to plasma/urine respectively
2 Data obtained from mean values of 6 replicates for TCA; 4 for MeCN and MeOH
3 Met acceptance criteria of CV(%)s being < = 15%.
t the LLOQ. At the LLOQ, the detector response was required to be
t least ﬁve times that obtained using a blank sample.
.7.6. Matrix effects
Matrix effects were assessed using the method reported by
atuszewski et al [30]. Six batches of blank plasma and urine were
nalysed after being spiked with MC  at the same nominal concen-
rations as the low and high QCs. These samples were extracted
longside aqueous reference solutions containing the same con-
entrations as the low and high QCs. All samples were analysed in
riplicate. A CV of ≤ 15% for the IS-normalised matrix factor (Table 2)
as deemed acceptable.
.7.7. Dilution integrity
Blank plasma and urine samples were prepared at concentra-
ions of twice and ten times the ULOQ. These were diluted 10-fold
nd 50-fold, respectively, with blank matrix prior to extraction.
ilution integrity was deemed acceptable if mean accuracy was
ithin ±15% of the nominal concentration and the CV was  ≤ 15%
or six replicates.
.7.8. Stability
The stability of MC  in plasma and urine was determined using
ow and high QCs under the following storage conditions: room
emperature, both protected from and exposed to light, refriger-
ted at ca. 4 ◦C, frozen at ca. -20 ◦C and ca. -80 ◦C and for up to six
reeze/thaw cycles. Stability of extracts was assessed after refriger-
tion at ca. 4 ◦C, undiluted and diluted, and in the autosampler tray
et to 4 ◦C. Freshly extracted samples were used as comparators.
ean baseline and nominal values were used to assess stability.
tock and working solutions of MC  and IS were assessed after stor-
ge at ca.-80 ◦C by comparison with freshly prepared solutions.
.7.9. Ionisation effects and extraction recovery
Ionisation effects and extraction recoveries were determined
sing blank matrix samples spiked after extraction. The concen-
rations in the ﬁnal extracts were set to be equivalent to 100%
xtraction recovery for the low, medium and high QCs, and the IS.
onisation effects were assessed by comparing the responses with
hose obtained from matrix-free solutions at the same QC levels.
xtraction recoveries were assessed by comparing the responses
f the samples spiked after extraction with those from the corre-
ponding QCs. The mean values from six replicates for each sample
ere used for the assessment. A CV of ≤ 15% for the recoveries at
ach QC level was deemed acceptable with one QC level being used
or assessing the IS.wed by 10-fold dilution with water.
2.8. Application to clinical samples
The fully validated methods for MC  in plasma and urine were
applied to samples collected during the clinical study described ear-
lier. Blood samples were collected in EDTA-containing vacutainers
[18,19]. These were centrifuged at 2000 g for 10 min  at 4 ◦C then
immediately transferred to storage at ca. -80 ◦C. Test samples were
transported frozen, on dry ice, for analysis at Southmead Hospital,
Bristol, UK. Two  replicates of the low, medium and high QCs were
interspersed throughout each analytical run.
2.9. Incurred sample reanalysis (ISR)
A minimum of 5% of plasma and urine samples from the safety
and tolerability study were reanalysed. Results from the reanalyses
were compared to the original values. ISR was  deemed acceptable
when the percentage difference between the pairs of results was
< = 20% for > = 66.7% of the samples.
3. Results & discussion
3.1. Optimisation of the chromatographic conditions and
robustness of the HPLC-MS/MS system
In the absence of an ion-pairing agent, adequate separation of
MC  from 4-EMC with an acceptable chromatographic peak shape
could not be obtained with a mobile phase containing acetonitrile
on the following range of stationary phases, packed in 50 x 2.1 mm
ID columns: 2.7 m HaloTM C18, 2.6 m KinetexTM XB-C18, 2.6 m
AccucoreTM AQ and 2.6 m AccucoreTM Phenyl-Hexyl. Methanol,
combined with 5 mM aqueous ammonium formate on a XBridge
BEH C18 stationary phase gave the best compromise between the
resolution of MC  from 4-EMC and the injection cycle time, on a
conventional LC system. Reducing the pH to 2 removed the res-
olution whilst increasing the pH to 3 led to improved resolution
but signiﬁcantly longer retention times. Unlike reported elsewhere
[18], the assays described here avoid the use of an ion pairing
agent but use the following: a wash stage for the column with
each injection cycle, diversion of eluate from the MS and a pre-
column ﬁlter. In our view, this approach increases the lifetimes of
the columns, reduces contamination of the LC system and avoids
time-consuming, potentially costly, additional maintenance of the
MS.  This was demonstrated by the robustness of the assays when
applied to clinical samples.
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Fig. 3. Representative chromatograms from plasma validation samples.
Table 3
Stability of Minocycline in plasma and urine.
Test/temperature Time/cycle QC
Plasma1 Urine1
Meanaccuracy(%) CV (%) Meanaccuracy(%) CV (%)
RT/protected
from light
0 (baseline)
Low 88.2 1.75 95.0 2.74
High 92.9 2.05 94.3 1.02
6  hours
Low 90.4 4.50 95.8 0.402
High 88.9 4.36 95.6 3.09
RT/exposed to light
0 (baseline)
Low 88.2 1.75 98.0 6.78
High 92.9 2.06 91.4 2.11
6  hours
Low 97.3 4.17 94.6 2.83
High 99.7 3.50 91.1 2.30
Freeze-thaw cycles1
0 (baseline) Low 103 6.15 109 7.14
High 100 8.57 103 2.43
last  cycle Low 1162 7.62 103 3.56
High 97.2 3.84 95.7 1.65
ca.  4 ◦C
0 (baseline) Low 93.3 4.56 102 5.10
High 94.6 2.58 91.5 3.03
24  hours Low 90.2 8.66 91.6 4.06
High 94.3 1.35 88.9 3.90
ca.  -80 ◦C
0 (baseline) Low 99.8 3.01 107 2.12
High 108 3.72 101 3.29
6  Months Low 96.2 4.72 107 1.57
High 114 7.78 110 0.438
Accuracy of mean and CV (%) obtained from 3 individual replicates.
A
2
3
r
d
p
l
w
T
b
o
A
tbbreviations: RT = Room temperature.
Accepted as within 15% of baseline value.
1 6 cycles for plasma and 5 cycles for urine.
.2. Choice of extraction method and epimerisation
Chromatographic separation of MC  from 4-EMC in a matrix-free
eference solution is demonstrated in Fig. 3. TCA has not been the
eproteinising agent of choice when extracting TCs from serum or
lasma. Here, TCA gave higher sensitivity as the ﬁnal extract was
ess dilute, extraction recoveries were similar and ion suppression
as reduced, when compared to acetonitrile or methanol (Table 2).
he concern that TCA could catalyse epimerisation was  shown to
e unfounded by the results of the investigations into the stability
f MC  and the IS in stored extracts (Tables 3 and 4, Figs. 3 and 4).
s this applied to both urine and EDTA-plasma, it is theorised that
he ion pairing properties of TCA are mainly responsible.3.3. Ionisation effects, extraction recoveries and choice of IS
The similar ionisation properties and extraction recoveries of
the IS (Table 2) compared to MC,  its stability in sample extracts
(Table 3) and the robustness of the assays supported the use of a
structural analogue, tetracycline, as an IS. This was  a cheaper and
more accessible alternative to deuterated minocycline. Ionisation
effects and extraction recoveries met  the acceptance criteria.3.4. Method validations
The assays described here met  all the validation criteria outlined
earlier with respect to the calibration model, selectivity, carryover,
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Table  4
Stability of Minocycline and IS in plasma and urine extracts at ca. 4 ◦C.
Test conditions Time QC
Accuracy of mean (%)
Plasma Urine
Autosampler
tray
0 (baseline)
LLOQ 89.9 115
2xLLOQ 92.2 99.0
Low 93.7 102
Medium 99.0 104
High 96.0 98.9
7  days
LLOQ 88.7 101
2xLLOQ 92.0 101
Low 90.3 102
Medium 97.5 107
High 96.0 101
Refrigerated
0  (baseline)
LLOQ 106 115
2xLLOQ 96.0 113
Low 99.8 102
Medium 92.7 104
High 108 98.9
5  days (plasma)
7 days (urine)
LLOQ 106 111
2xLLOQ 96.0 103
Low 99.8 102
Medium 92.7 95.0
High 108 89.9
Refrigerated
(undiluted)
0  (baseline)
LLOQ 106 115
2xLLOQ 96.0 113
Low 95.6 102
Medium 92.7 104
High 93.6 98.9
5  days
LLOQ 88.4 98.7
2xLLOQ 86.5 93.0
Low 95.1 99.4
Medium 103 105
High 94.2 95.3
rom u
a
T
0
i
e
u
<Fig. 4. Chromatograms f
ccuracy, precision, matrix effects and dilution integrity (Table 5).
he validated ranges were 0.05–30 mg/L for human plasma and
.1–30 mg/L for human urine. Peaks for MC  and IS were not detected
n the carryover test samples nor in the 6 blank plasma samples
valuated for matrix effects. MC  was detected in 2 of the 36 blank
rine replicates tested for matrix effects but the response was
 = 20% of the LLOQ calibration standard.rine validation samples.
3.5. Stability of MC  in plasma and urine samples
MC  was stable in plasma at room temperature, protected from
and exposed to light, for up to 6 h, refrigerated for 24 h, for up to six
freeze-thaw cycles and after ca. six months at ca. -80 ◦C (Table 3).
MC was stable in urine under the same conditions but was  tested
for only up to ﬁve freeze-thaw cycles Table 3).
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Table 5
Summary of validation results.
Test Property
Plasma Urine
QC Value n Value n
Calibration Model
Correlation coefﬁcient – 0.997±0.000885 28 0.998±0.000803 26
Failed calibrators – 23 (3.87%) 594 8 (1.55%) 515
Dilution integrity
Accuracy (%)
60 mg/L 93.6 6 104 6
300 mg/L 99.6 6 94.4 6
Precision, CV (%)
60 mg/L 7.23 6 5.75 6
300 mg/L 3.71 6 8.27 6
IS-normalised
Matrix Effects**
Mean (%)
Low 1.32 6 1.02 6
High 1.17 6 0.951 6
Precision, CV (%)
Low 1.98 6 4.67 6
High 1.96 6 4.04 6
Intra-run accuracy
and precision
Accuracy (%)
LLOQ 116 6 106 6
2xLLOQ 108 6 101 6
Low 109 6 105 6
Medium 105 6 103 6
High 98.6 6 104 6
Precision, CV (%)
LLOQ 7.68 6 4.39 6
2xLLOQ 4.94 6 3.46 6
Low 4.22 6 2.53 6
Medium 2.99 6 4.51 6
High 2.18 6 2.72 6
Inter-run accuracy
and precision
Accuracy (%)
LLOQ 109 16 101 18
2xLLOQ 103 22 98.6 18
Low 97.3 18 100 18
Medium 101 22 102 18
High 96.4 20 98.1 18
Precision, CV (%)
LLOQ 14.6 16 9.43 18
2xLLOQ 13.0 22 5.50 18
Low 8.88 18 7.88 18
Medium 8.73 22 6.37 18
High 5.64 20 5.36 18
n = number of replicates or individual calibrators.
Analyte matrix factor (%) = 100 x analyte peak area of plasma or urine sample/analyte peak area of aqueous solution. IS matrix factor (%) = 100 x IS peak area of plasma/urine
sample/IS peak area of aqueous solution. For each sample, IS-normalised matrix factor = Analyte matrix factor /IS matrix factor. Mean and precision calculated from 3 replicates
for  each of 6 blank samples.
3
a
e
M
f
wFig. 5. Chromatograms from clinical plasma samples.
.6. Stability of MC  and IS in plasma and urine extracts at 4 ◦C
nd in working solutions
MC  and the IS were stable for up to 7 days in plasma and urine
xtracts, stored in the autosampler tray or in a refrigerator (Table 2).
C and the IS were stable in un-diluted extracts, containing 5% TCA,
or at least 5 days (Table 2). MC  was stable at ca. -80 ◦C in stock and
orking solutions stored at for up to 321 and 83 days respectively.Fig. 6. Chromatograms from clinical urine samples.
The IS was stable in the intermediate, aqueous, working solution,
at a concentration of 200 mg/L, for up to 279 days at ca. -80 ◦C.
3.7. Application to clinical samples
The robustness of the assays when applied to clinical samples
is demonstrated in Table 6. For the purpose of ISRs, 99 of the 1423
plasma samples (6.96%) and 75 of the 689 urine samples (10.9%)
were reanalysed. The results met  the acceptance criteria that the
difference between the original and repeat results should be <20%
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Table  6
Performance of calibrators and QCs in application to a Phase 1 clinical study.
QC
Plasma Urine
Accuracy of mean (%) Precision, CV (%) n Failure rate (%) Accuracy of mean (%) Precision, CV (%) n Failure rate (%)
Failed calibrators 1177 3.57 Failed calibrators 538 2.23
Low  106 9.30 116 13.8 102 8.60 50 6.00
Medium 107 7.69 118 11.9 104 3.43 52 1.92
High  104 5.61 118 2.54 96.5 3.89 51 3.92
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or > = 67% of ISRs. This also demonstrated the stability of MC  and
ack of signiﬁcant epimerisation in both stored and reanalysed clin-
cal samples (Figs. 5 and 6). The chromatographic resolution was
articularly important for urine samples collected at later time
oints (Fig. 6) because of an abundance of 4-EMC.
. Conclusion
Novel, uncomplicated, HPLC-MS/MS based assays for minocy-
line, a tetracycline antibiotic, in human plasma and urine have
een developed and validated. An analogue internal standard,
etracycline, and a simple deproteinising step were used. The assays
ere successfully used to generate PK data from a Phase 1 clinical
tudy. This is an example of modern analytical technology being
sed in support of a new application of an old drug that is still
ffective and widely used.
onﬂict of interest
All authors declare no conﬂicts of interest.
unding/support
This research project receives support from the Innovative
edicines Initiative Joint Undertaking under grant agreement n◦
15523 | 115620 | 115737 | 777362 resources of which are com-
osed of ﬁnancial contribution from the European Union Seventh
ramework Programme (FP7/2007-2013) and EFPIA companies in
ind contribution.
cknowledgements
The research leading to these results was conducted as part of
he COMBACTE consortium. For further information please refer to
www.COMBACTE.com).
The authors thank Felicity Elder, David Hardy and Kate Ellery
NBT, Bristol) for the initial development work and assistance with
he analyses of samples from clinical studies. The authors also thank
liver Cornely, Vassiliki Dimitriou and Dorothee Arenz (University
ospital Cologne, Cologne, Germany) and Olivier Barraud (Univer-
ity Hospital Center Limoges, Limoges) France for their roles in
he clinical studies, Karen Fusaro (Melinta Therapeutics Inc., Lin-
olnshire, IL, USA), Elizabeth Morgan, Jeffery Loutit (The Medicines
ompany San Diego, CA, USA) and Joe Hamilton (Project Manage-
ent Now, Arlington, VA, USA) for their support of the publication.
eferences[1] G.S. Redin, Antibacterial activity in mice of minocycline, a new tetracycline,
Antimicrob. Agents Chemother. 6 (1966) 371–376.
[2] N.A. Kuck, G.S. Redin, M.  Forbes, Activity of minocycline and other
tetracyclines against tetracycline-sensitive and -resistant Staphylococci, Proc.
Soc. Exp. Biol. Med. 136 (2) (1971) 479–481.
[[3] R.N. Brogden, G.S. Avery, New antibiotics: epicillin, minocycline and
spectinomycin a summary of their antibacterial activity, pharmacokinetic
properties and therapeutic efﬁcacy, Drugs 3 (5) (1972) 314–330.
[4] F. Bahrami, D.L. Morris, M.H. Pourgholami, Tetracyclines: drugs with huge
therapeutic potential, Mini-Rev. Med. Chem. 12 (1) (2012) 44–52.
[5] M.  Barza, R.B. Brown, C. Shanks, C. Gamble, L. Weinstein, Relation between
lipophilicity and pharmacological behavior of minocycline, doxycycline,
tetracycline, and oxytetracycline in dogs, Antimicrob. Agents Chemother. 8
(6)  (1975) 713–720.
[6] S. Saivin, G. Houin, Clinical pharmacokinetics of doxycycline and minocycline,
Clin. Pharmacokinet. 15 (6) (1988) 355–366.
[7] N. Garrido-Mesa, A. Zarzuelo, J. Gálvez, Minocycline: Far beyond an antibiotic,
Br. J. Pharmacol. 169 (2) (2013) 337–352.
[8] E. Bishburg, K. Bishburg, Minocycline-an old drug for a new century:
emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and
Acinetobacter baumannii, Int. J. Antimicrob. Agents 34 (5) (2009) 395–401.
[9] D.M. Shlaes, D. Sahm, C. Opiela, B. Spellberg, The FDA reboot of antibiotic
development, Antimicrob. Agents Chemother. 57 (10) (2013) 4605.
10] GENERATING ANTIBIOTIC INCENTIVES NOW (GAIN) Act, in: D.o.H.a.H.
Services (Ed.), 2012, USA.
11] Antibiotic Resistance Threats in the United States., in: C.f.D.C. and, P. (CDC)
(Eds.), 2013.
12] Questions and Answers on Patient Safety, Including the Prevention and
Control of Healthcare Associated Infections, European Commission, Brussels,
2008.
13] L.S. Munoz-Price, R.A. Weinstein, Acinetobacter Infection, N. Engl. J. Med. 358
(12) (2008) 1271–1281.
14] D.J. Ritchie, A. Garavaglia-Wilson, A review of intravenous minocycline for
treatment of multidrug-resistant acinetobacter infections, Clin. Infect. Dis. 59
(2014) S374–S380.
15] O.A. Cornely, O. Barraud, M.  Bayliss, V. Dimitriou, A.M. Lovering, A.
MacGowan, S.K. Cammarata, K. Fusaro, D.C. Grifﬁth, Phase I Study to Evaluate
the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of
Intravenous Minocycline in Healthy Adult Subjects, IDWeek 2018, San
Francisco, CA, USA, 2018.
16] K.N. Agwuh, A. MacGowan, Pharmacokinetics and pharmacodynamics of the
tetracyclines including glycylcyclines, J. Antimicrob. Chemother. 58 (2) (2006)
256–265.
17] P.G. Welling, W.R. Shaw, S.J. Uman, F.L. Tse, W.A. Craig, Pharmacokinetics of
minocycline in renal failure, Antimicrob. Agents Chemother. 8 (5) (1975)
532–537.
18] D.S. Patel, N. Sharma, M.C. Patel, B.N. Patel, P.S. Shrivastav, M.  Sanyal, Analysis
of  a second-generation tetracycline antibiotic minocycline in human plasma
by  LC-MS/MS, Bioanalysis 3 (19) (2011) 2177–2194.
19] M.V.F. Araujo, D.R. Ifa, W.  Ribeiro, M.E. Moraes, M.O. Moraes, G. De Nucci,
Determination of minocycline in human plasma by high-performance liquid
chromatography coupled to tandem mass spectrometry: application to
bioequivalence study, J. Chromatogr. B Biomed. Sci. Appl. 755 (1-2) (2001)
1–7.
20] C.R. Anderson, H.S. Rupp, W.H. Wu,  Complexities in tetracycline analysis -
Chemistry, matrix extraction, cleanup, and liquid chromatography, J.
Chromatogr. A 1075 (1-2) (2005) 23–32.
21] D.A. Hussar, P.J. Niebergall, E.T. Sugita, J.T. Doluisio, Aspects of the
epimerization of certain tetracycline derivatives, J. Pharm. Pharmacol. 20 (7)
(1968) 539–546.
22] M.L. Nelson, Chapter 11. The chemistry and biology of the tetracyclines, in:
Annual Reports in Medicinal Chemistry, 2002, pp. 105–114.
23] R.G. Kelly, L.A. Kanegis, Metabolism and tissue distribution of radioisotopically
labeled minocycline, Toxicol. Appl. Pharmacol. 11 (1) (1967) 171–183.
24] H.J.C.F. Nelis, A.P. De Leenheer, Metabolism of minocycline in humans, DRUG
METAB, DISPOS 10 (2) (1982) 142–146.
25] M.  Grote, Antibiotics in the environment and food. A risk for consumers?
Internist. Prax. 47 (4) (2007) 919–926.
26] H. Han, H. Xiao, Z. Lu, Short-term toxicity assessments of an antibiotic
metabolite in Wistar rats and its metabonomics analysis by ultra-high
performance liquid chromatography coupled to quadrupole time-of-ﬂight
mass spectrometry, Toxicol. Appl. Pharmacol. 293 (2016) 1–9.
27] European Medicines Agency, Guideline on Bioanalytical Method Validation,
2011, EMA/CHMP/EWP/192217/2009. https://www.ema.europa.eu/
9 tical a
[
[
incorrect weighting factors on curve stability, data quality, and assay
performance, Anal. Chem. 86 (18) (2014) 8959–8966.8 M.A.J. Bayliss et al. / Journal of Pharmaceu
documents/scientiﬁc-guideline/guideline-bioanalytical-method-validation
en.pdf.
28] U.S. Food and Drug Administration, Guidance for Industry: Bioanalytical
Method Validation, 2001, Updated in 2013 and 2018 https://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM070107.pdf.
29] H. Gu, G. Liu, J. Wang, A.F. Aubry, M.E. Arnold, Selecting the correct weighting
factors for linear and quadratic calibration curves with least-squares
[nd Biomedical Analysis 169 (2019) 90–98
regression algorithm in bioanalytical LC-MS/MS assays and impacts of using30] B.K. Matuszewski, M.L. Constanzer, C.M. Chavez-Eng, Strategies for the
assessment of matrix effect in quantitative bioanalytical methods based on
HPLC-MS/MS, Anal. Chem. 75 (13) (2003) 3019–3030.
